Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Oxygenta Pharmaceutical Ltd. stands out as a sector laggard, exhibiting negative financial metrics across growth, profitability, and valuation, with no revenues or profits, while peers demonstrate diverse strengths. Companies like Sun Pharmaceutical and Dr. Reddy's Laboratories show strong profitability and growth, contrasting sharply with Oxygenta's performance.
Highest revenue growth YoY (8.42%) and strong EPS (45.55) with a solid ROE (16.13%).
High profitability with an ROE of 21.76% and consistent revenue growth.
Strong growth trajectory with a YoY revenue increase of 13.28% and a competitive ROE of 16.63%.